[go: up one dir, main page]

EP1692318A4 - Compositions and methods to diagnose and treat lung cancer - Google Patents

Compositions and methods to diagnose and treat lung cancer

Info

Publication number
EP1692318A4
EP1692318A4 EP04812984A EP04812984A EP1692318A4 EP 1692318 A4 EP1692318 A4 EP 1692318A4 EP 04812984 A EP04812984 A EP 04812984A EP 04812984 A EP04812984 A EP 04812984A EP 1692318 A4 EP1692318 A4 EP 1692318A4
Authority
EP
European Patent Office
Prior art keywords
diagnose
compositions
methods
lung cancer
treat lung
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04812984A
Other languages
German (de)
French (fr)
Other versions
EP1692318A2 (en
Inventor
Bruce L Roberts
Srinivas Shankara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of EP1692318A2 publication Critical patent/EP1692318A2/en
Publication of EP1692318A4 publication Critical patent/EP1692318A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
EP04812984A 2003-12-02 2004-12-02 Compositions and methods to diagnose and treat lung cancer Withdrawn EP1692318A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52652803P 2003-12-02 2003-12-02
PCT/US2004/040576 WO2005055808A2 (en) 2003-12-02 2004-12-02 Compositions and methods to diagnose and treat lung cancer

Publications (2)

Publication Number Publication Date
EP1692318A2 EP1692318A2 (en) 2006-08-23
EP1692318A4 true EP1692318A4 (en) 2008-04-02

Family

ID=34676625

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04812984A Withdrawn EP1692318A4 (en) 2003-12-02 2004-12-02 Compositions and methods to diagnose and treat lung cancer

Country Status (3)

Country Link
EP (1) EP1692318A4 (en)
JP (1) JP2007518399A (en)
WO (1) WO2005055808A2 (en)

Families Citing this family (188)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006094014A2 (en) 2005-02-28 2006-09-08 The Regents Of The University Of California Methods for diagnosis and treatment of endometrial cancer
WO2006113526A2 (en) 2005-04-15 2006-10-26 The Regents Of The University Of California Prevention of chlamydia infection using a protective antibody
US8648052B2 (en) 2005-04-15 2014-02-11 The Regents Of The University Of California Prevention of chlamydia infection using SIRNA
US8318906B2 (en) 2005-04-15 2012-11-27 The Regents Of The University Of California EMP2 antibodies and their therapeutic uses
JP5911805B2 (en) 2009-11-20 2016-04-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Epithelial membrane protein-2 (EMP2) and proliferative vitreoretinopathy (PVR)
UY35468A (en) 2013-03-16 2014-10-31 Novartis Ag CANCER TREATMENT USING AN ANTI-CD19 CHEMERIC ANTIGEN RECEIVER
WO2015066413A1 (en) 2013-11-01 2015-05-07 Novartis Ag Oxazolidinone hydroxamic acid compounds for the treatment of bacterial infections
US20150140036A1 (en) 2013-11-13 2015-05-21 Novartis Institutes For Biomedical Research, Inc. Low, immune enhancing, dose mtor inhibitors and uses thereof
WO2015090230A1 (en) 2013-12-19 2015-06-25 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
JO3517B1 (en) 2014-01-17 2020-07-05 Novartis Ag N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody Molecules of PD-1 and Their Uses
JOP20200096A1 (en) 2014-01-31 2017-06-16 Children’S Medical Center Corp Antibody molecules to tim-3 and uses thereof
CA2936962C (en) 2014-03-14 2024-03-05 Novartis Ag Antibody molecules to lag-3 and uses thereof
ES2939760T3 (en) 2014-03-15 2023-04-26 Novartis Ag Cancer treatment using a chimeric receptor for antigens
WO2015148379A1 (en) 2014-03-24 2015-10-01 Novartis Ag Monobactam organic compounds for the treatment of bacterial infections
PL3888674T3 (en) 2014-04-07 2024-09-23 Novartis Ag Treatment of cancer using anti-cd19 chimeric antigen receptor
JP7054622B2 (en) 2014-07-21 2022-04-14 ノバルティス アーゲー Treatment of cancer with humanized anti-BCMA chimeric antigen receptor
EP3722316A1 (en) 2014-07-21 2020-10-14 Novartis AG Treatment of cancer using a cd33 chimeric antigen receptor
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
JP2017528433A (en) 2014-07-21 2017-09-28 ノバルティス アーゲー Low immunoenhancing dose of mTOR inhibitor and CAR combination
ES2781175T3 (en) 2014-07-31 2020-08-31 Novartis Ag Optimized subset of T cells containing a chimeric antigen receptor
JP2017523213A (en) 2014-08-06 2017-08-17 ノバルティス アーゲー Quinolone derivatives as antibacterial agents
US10851149B2 (en) 2014-08-14 2020-12-01 The Trustees Of The University Of Pennsylvania Treatment of cancer using GFR α-4 chimeric antigen receptor
ES2791248T3 (en) 2014-08-19 2020-11-03 Novartis Ag Anti-CD123 chimeric antigen receptor (CAR) for use in cancer treatment
CA2960824A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of alk inhibitors
US10577417B2 (en) 2014-09-17 2020-03-03 Novartis Ag Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
EP3662903A3 (en) 2014-10-03 2020-10-14 Novartis AG Combination therapies
CN114107424A (en) 2014-10-08 2022-03-01 诺华股份有限公司 Biomarkers for predicting therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
MA41044A (en) 2014-10-08 2017-08-15 Novartis Ag COMPOSITIONS AND METHODS OF USE FOR INCREASED IMMUNE RESPONSE AND CANCER TREATMENT
CA2964367C (en) 2014-10-14 2024-01-30 Novartis Ag Antibody molecules to pd-l1 and uses thereof
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
SI3233843T1 (en) 2014-12-16 2019-12-31 Novartis Ag Isoxazole hydroxamic acid compounds as lpxc inhibitors
US20170340733A1 (en) 2014-12-19 2017-11-30 Novartis Ag Combination therapies
IL253149B2 (en) 2014-12-29 2023-11-01 Novartis Ag Methods for preparing cells expressing a chimeric receptor antigen
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
HK1247089A1 (en) 2015-03-10 2018-09-21 Aduro Biotech, Inc. Copositions and methods for activing "stimulator of interferon gene"-dependent signalling
WO2016164580A1 (en) 2015-04-07 2016-10-13 Novartis Ag Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
JP6961490B2 (en) 2015-04-08 2021-11-05 ノバルティス アーゲー CD20 therapy, CD22 therapy, and combination therapy with CD19 chimeric antigen receptor (CAR) expressing cells
WO2016168595A1 (en) 2015-04-17 2016-10-20 Barrett David Maxwell Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
US12128069B2 (en) 2015-04-23 2024-10-29 The Trustees Of The University Of Pennsylvania Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
AR105433A1 (en) 2015-07-21 2017-10-04 Novartis Ag METHODS TO IMPROVE THE EFFECTIVENESS AND EXPANSION OF IMMUNE CELLS
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
WO2017019896A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to pd-1
DK3317301T3 (en) 2015-07-29 2021-06-28 Immutep Sas COMBINATION THERAPIES INCLUDING ANTIBODY MOLECULES AGAINST LAYER-3
WO2017040930A2 (en) 2015-09-03 2017-03-09 The Trustees Of The University Of Pennsylvania Biomarkers predictive of cytokine release syndrome
NZ740616A (en) 2015-09-14 2023-05-26 Infinity Pharmaceuticals Inc Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
BR112018008891A8 (en) 2015-11-03 2019-02-26 Janssen Biotech Inc antibodies that specifically bind to pd-1 and tim-3 and their uses
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
CA3008102A1 (en) 2015-12-18 2017-06-22 Novartis Ag Antibodies targeting cd32b and methods of use thereof
EP3393504B1 (en) 2015-12-22 2025-09-24 Novartis AG Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
CA3009852A1 (en) 2015-12-28 2017-07-06 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
MX2018008592A (en) 2016-01-11 2018-12-10 Novartis Ag Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof.
US20200270265A1 (en) 2016-02-19 2020-08-27 Novartis Ag Tetracyclic pyridone compounds as antivirals
WO2017149515A1 (en) 2016-03-04 2017-09-08 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
FI3433257T3 (en) 2016-03-24 2024-01-08 Novartis Ag Alkynyl nucleoside analogs as inhibitors of human rhinovirus
CN109069638B (en) 2016-03-24 2022-03-29 璟尚生物制药公司 Trispecific inhibitors for cancer therapy
RU2018137110A (en) 2016-04-13 2020-05-13 Оримабс Лтд. ANTIBODIES AGAINST PSMA AND THEIR APPLICATION
SG11201810656WA (en) 2016-06-14 2018-12-28 Novartis Ag Crystalline form of (r)-4-(5-(cyclopropylethynyl)isoxazol-3-yl)-n-hydroxy-2-methyl-2-(methylsulfonyl)butanamide as an antibacterial agent
WO2017216686A1 (en) 2016-06-16 2017-12-21 Novartis Ag 8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
WO2017216685A1 (en) 2016-06-16 2017-12-21 Novartis Ag Pentacyclic pyridone compounds as antivirals
IL263680B2 (en) 2016-06-24 2025-10-01 Infinity Pharmaceuticals Inc Pi3k inhibitors for use in combination with a second therapeutic agent in treating, managing, or preventing cancer
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
CN116769050A (en) 2016-07-20 2023-09-19 犹他大学研究基金会 CD229 CAR T cells and methods of use thereof
WO2018047109A1 (en) 2016-09-09 2018-03-15 Novartis Ag Polycyclic pyridone compounds as antivirals
CA3037518A1 (en) 2016-09-21 2018-03-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptor (car) that targets chemokine receptor ccr4 and its use
JOP20190061A1 (en) 2016-09-28 2019-03-26 Novartis Ag Beta-lactamase inhibitors
WO2018067992A1 (en) 2016-10-07 2018-04-12 Novartis Ag Chimeric antigen receptors for the treatment of cancer
TW201819380A (en) 2016-10-18 2018-06-01 瑞士商諾華公司 Fused tetracyclic pyridone compounds as antivirals
MA46963A (en) 2016-12-03 2019-10-09 Juno Therapeutics Inc METHODS FOR DETERMINING THE DOSAGE OF CAR-T CELLS
SI3558955T1 (en) 2016-12-22 2021-12-31 Amgen Inc., Benzisothiazole, isothiazole (3,4-b) pyridine, quinazoline, phthalazine, pyrido (2,3-d) pyridazine and pyrido (2,3-D) pyrimidine derivatives as KRAS G12C inhibitors for the treatment of lung cancer, pancreatic cancer or colorectal cancer
EP3565839A4 (en) 2017-01-05 2021-04-21 Gensun Biopharma Inc. CHECKPOINT REGULATOR ANTAGONISTS
KR20200020662A (en) 2017-04-03 2020-02-26 온콜로지, 인크. How to Treat Cancer Using PS-Targeted Antibodies with Immuno-Oncology Agent
AR111419A1 (en) 2017-04-27 2019-07-10 Novartis Ag INDAZOL PIRIDONA FUSIONED COMPOUNDS AS ANTIVIRALS
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
US20200055948A1 (en) 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
UY37695A (en) 2017-04-28 2018-11-30 Novartis Ag BIS 2’-5’-RR- (3’F-A) (3’F-A) CYCLE DINUCLEOTIDE COMPOUND AND USES OF THE SAME
UY37718A (en) 2017-05-05 2018-11-30 Novartis Ag 2-TRYCLINAL QUINOLINONES AS ANTIBACTERIAL AGENTS
JOP20190272A1 (en) 2017-05-22 2019-11-21 Amgen Inc Kras g12c inhibitors and methods of using the same
AU2018275109A1 (en) 2017-06-01 2020-01-02 Xencor, Inc. Bispecific antibodies that bind CD 123 CD3
WO2018223004A1 (en) 2017-06-01 2018-12-06 Xencor, Inc. Bispecific antibodies that bind cd20 and cd3
WO2018223101A1 (en) 2017-06-02 2018-12-06 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
WO2018226336A1 (en) 2017-06-09 2018-12-13 Providence Health & Services - Oregon Utilization of cd39 and cd103 for identification of human tumor reactive cells for treatment of cancer
CA3067602A1 (en) 2017-06-29 2019-01-03 Juno Therapeutics, Inc. Mouse model for assessing toxicities associated with immunotherapies
EP3679040B1 (en) 2017-09-08 2022-08-03 Amgen Inc. Inhibitors of kras g12c and methods of using the same
CN111566124A (en) 2017-10-25 2020-08-21 诺华股份有限公司 Methods of making cells expressing chimeric antigen receptors
KR20200074997A (en) 2017-11-01 2020-06-25 주노 쎄러퓨티크스 인코퍼레이티드 Antibodies and chimeric antigen receptors specific for B-cell maturation antigens
PL3703750T3 (en) 2017-11-01 2025-04-07 Juno Therapeutics, Inc. Chimeric antigen receptors specific for b-cell maturation antigen and encoding polynucleotides
US12031975B2 (en) 2017-11-01 2024-07-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
EP3710455A1 (en) 2017-11-17 2020-09-23 Novartis AG Novel dihydroisoxazole compounds and their use for the treatment of hepatitis b
EP3716980A1 (en) 2017-12-01 2020-10-07 Juno Therapeutics, Inc. Methods for dosing and for modulation of genetically engineered cells
CN112204048A (en) 2017-12-15 2021-01-08 朱诺治疗学股份有限公司 Anti-CCT5 binding molecules and methods of use
WO2019123285A1 (en) 2017-12-20 2019-06-27 Novartis Ag Fused tricyclic pyrazolo-dihydropyrazinyl-pyridone compounds as antivirals
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
EP3759110A1 (en) 2018-02-28 2021-01-06 Novartis AG Indole-2-carbonyl compounds and their use for the treatment of hepatitis b
WO2019184909A1 (en) 2018-03-27 2019-10-03 信达生物制药(苏州)有限公司 Novel antibody molecule, and preparation method and use thereof
CN110305210B (en) 2018-03-27 2023-02-28 信达生物制药(苏州)有限公司 Novel antibody molecules, methods of making and uses thereof
WO2019210153A1 (en) 2018-04-27 2019-10-31 Novartis Ag Car t cell therapies with enhanced efficacy
US20210396739A1 (en) 2018-05-01 2021-12-23 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
JP7266043B2 (en) 2018-05-04 2023-04-27 アムジエン・インコーポレーテツド KRas G12C inhibitors and methods of using them
MA52496A (en) 2018-05-04 2021-03-10 Amgen Inc KRAS G12C INHIBITORS AND THEIR PROCEDURES FOR USE
MA52564A (en) 2018-05-10 2021-03-17 Amgen Inc KRAS G12C INHIBITORS FOR CANCER TREATMENT
US20210213063A1 (en) 2018-05-25 2021-07-15 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
WO2019232528A1 (en) 2018-06-01 2019-12-05 Xencor, Inc. Dosing of a bispecific antibody that bind cd123 and cd3
MA52765A (en) 2018-06-01 2021-04-14 Amgen Inc KRAS G12C INHIBITORS AND THEIR PROCEDURES FOR USE
US20190375749A1 (en) 2018-06-11 2019-12-12 Amgen Inc. Kras g12c inhibitors and methods of using the same
MA51848A (en) 2018-06-12 2021-04-21 Amgen Inc KRAS G12C INHIBITORS AND THEIR PROCEDURES FOR USE
TWI890660B (en) 2018-06-13 2025-07-21 瑞士商諾華公司 Bcma chimeric antigen receptors and uses thereof
US11001635B2 (en) 2018-06-29 2021-05-11 Gensun Biopharma Inc. Antitumor antagonists
WO2020047449A2 (en) 2018-08-31 2020-03-05 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
SG11202101825QA (en) 2018-08-31 2021-03-30 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
AU2019336197A1 (en) 2018-09-07 2021-02-18 Pfizer Inc. Anti-avb8 antibodies and compositions and uses thereof
WO2020053654A1 (en) 2018-09-12 2020-03-19 Novartis Ag Antiviral pyridopyrazinedione compounds
EP3856779A1 (en) 2018-09-28 2021-08-04 Novartis AG Cd22 chimeric antigen receptor (car) therapies
EP3856782A1 (en) 2018-09-28 2021-08-04 Novartis AG Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
BR112021005606A2 (en) 2018-09-29 2021-06-22 Novartis Ag process of producing a compound to inhibit the activity of shp2
PE20211058A1 (en) 2018-11-01 2021-06-07 Juno Therapeutics Inc SPECIFIC CHEMERIC ANTIGEN RECEPTORS FOR MEMBER D OF GROUP 5 OF CLASS C OF THE RECEPTOR COUPLED TO PROTEIN G (GPRC5D)
CA3117419A1 (en) 2018-11-01 2020-05-07 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
KR20210104713A (en) 2018-11-16 2021-08-25 주노 쎄러퓨티크스 인코퍼레이티드 Engineered T-cell dosing methods for treatment of B-cell malignancies
JP7516029B2 (en) 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Improved synthesis of key intermediates for KRAS G12C inhibitor compounds
JP7377679B2 (en) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド Combination therapy comprising a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer
EP3883565A1 (en) 2018-11-19 2021-09-29 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2020113194A2 (en) 2018-11-30 2020-06-04 Juno Therapeutics, Inc. Methods for treatment using adoptive cell therapy
IL283639B2 (en) 2018-12-20 2024-06-01 Amgen Inc KIF18A inhibitors
US12459932B2 (en) 2018-12-20 2025-11-04 Amgen Inc. KIF18A inhibitors
CA3123227A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
WO2020132653A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
WO2020160050A1 (en) 2019-01-29 2020-08-06 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
US20230148450A9 (en) 2019-03-01 2023-05-11 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
KR20210146288A (en) 2019-03-01 2021-12-03 레볼루션 메디슨즈, 인크. Bicyclic heterocyclyl compounds and uses thereof
US20220168389A1 (en) 2019-04-12 2022-06-02 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
WO2020219742A1 (en) 2019-04-24 2020-10-29 Novartis Ag Compositions and methods for selective protein degradation
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
JP7092935B2 (en) 2019-05-21 2022-06-28 アムジエン・インコーポレーテツド Solid form
EP3990116A1 (en) 2019-06-28 2022-05-04 Gensun Biopharma Inc. ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFß1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD
CN114401953A (en) 2019-08-02 2022-04-26 美国安进公司 KIF18A inhibitors
MX2022001302A (en) 2019-08-02 2022-03-02 Amgen Inc KIF18A INHIBITORS.
JP7640521B2 (en) 2019-08-02 2025-03-05 アムジエン・インコーポレーテツド Heteroaryl amides useful as KIF18A inhibitors - Patents.com
US20220289724A1 (en) 2019-08-02 2022-09-15 Amgen Inc. Kif18a inhibitors
CA3155287A1 (en) 2019-09-26 2021-04-01 Novartis Ag Antiviral pyrazolopyridinone compounds
MX2022004656A (en) 2019-10-24 2022-05-25 Amgen Inc PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF KRAS G12C AND KRAS G12D IN THE TREATMENT OF CANCER.
CR20220241A (en) 2019-11-04 2022-08-03 Revolution Medicines Inc RAS INHIBITORS
BR112022008535A2 (en) 2019-11-04 2022-08-09 Revolution Medicines Inc COMPOUND, PHARMACEUTICAL COMPOSITION, METHODS TO TREAT CANCER AND A RAS PROTEIN DISORDER
US11739074B2 (en) 2019-11-04 2023-08-29 Revolution Medicines, Inc. Ras inhibitors
BR112022008858A2 (en) 2019-11-08 2022-09-06 Revolution Medicines Inc COMPOUND, PHARMACEUTICAL COMPOSITION AND METHODS FOR INHIBITING SOS1 IN A SUBJECT, FOR INHIBITING THE INTERACTION OF SOS1 AND A PROTEIN, TO TREAT OR PREVENT A DISEASE AND TO TREAT OR PREVENT CANCER
MX2022005708A (en) 2019-11-14 2022-06-08 Amgen Inc IMPROVED SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND.
TW202132271A (en) 2019-11-14 2021-09-01 美商安進公司 Improved synthesis of kras g12c inhibitor compound
AR120566A1 (en) 2019-11-26 2022-02-23 Novartis Ag CHIMERIC ANTIGEN RECEPTORS AND THEIR USES
BR112022009679A2 (en) 2019-11-26 2022-08-09 Novartis Ag CD19 AND CD22 CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
CN114980976A (en) 2019-11-27 2022-08-30 锐新医药公司 Covalent RAS inhibitors and uses thereof
IL294484A (en) 2020-01-07 2022-09-01 Revolution Medicines Inc Dosage for shp2 inhibitor and methods for treating cancer
WO2021163618A1 (en) 2020-02-14 2021-08-19 Novartis Ag Method of predicting response to chimeric antigen receptor therapy
KR20220147109A (en) 2020-02-27 2022-11-02 노파르티스 아게 Methods for making chimeric antigen receptor-expressing cells
TW202146452A (en) 2020-02-28 2021-12-16 瑞士商諾華公司 Dosing of a bispecific antibody that binds cd123 and cd3
WO2021207689A2 (en) 2020-04-10 2021-10-14 Juno Therapeutics, Inc. Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen
EP4168002A1 (en) 2020-06-18 2023-04-26 Revolution Medicines, Inc. Methods for delaying, preventing, and treating acquired resistance to ras inhibitors
IL301062A (en) 2020-09-03 2023-05-01 Revolution Medicines Inc Use of SOS1 inhibitors to treat malignancies with SHP2 mutations
US11690915B2 (en) 2020-09-15 2023-07-04 Revolution Medicines, Inc. Ras inhibitors
IL302700A (en) 2020-11-13 2023-07-01 Novartis Ag Combined treatments with cells expressing chimeric antigens (vehicle)
US20240050432A1 (en) 2020-12-08 2024-02-15 Infinity Pharmaceuticals, Inc. Eganelisib for use in the treatment of pd-l1 negative cancer
CA3203111A1 (en) 2020-12-22 2022-06-30 Kailiang Wang Sos1 inhibitors and uses thereof
EP4334324A1 (en) 2021-05-05 2024-03-13 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
EP4334325A1 (en) 2021-05-05 2024-03-13 Revolution Medicines, Inc. Ras inhibitors for the treatment of cancer
IL308193A (en) 2021-05-05 2024-01-01 Revolution Medicines Inc Ras inhibitors
TW202307210A (en) 2021-06-01 2023-02-16 瑞士商諾華公司 Cd19 and cd22 chimeric antigen receptors and uses thereof
EP4351595A1 (en) 2021-06-07 2024-04-17 Providence Health & Services - Oregon Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
CA3231180A1 (en) 2021-09-08 2023-03-16 Redona Therapeutics, Inc. Papd5 and/or papd7 inhibiting 4-oxo-1,4-dihydroquinoline-3-carboxylic acid derivatives
AR127308A1 (en) 2021-10-08 2024-01-10 Revolution Medicines Inc RAS INHIBITORS
US20250282782A1 (en) 2021-12-17 2025-09-11 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023154905A1 (en) 2022-02-14 2023-08-17 Gilead Sciences, Inc. Antiviral pyrazolopyridinone compounds
MX2024010828A (en) 2022-03-07 2024-09-17 Amgen Inc A process for preparing 4-methyl-2-propan-2-yl-pyridine-3-carboni trile.
CN119136806A (en) 2022-03-08 2024-12-13 锐新医药公司 Methods for treating immune-refractory lung cancer
EP4536364A1 (en) 2022-06-10 2025-04-16 Revolution Medicines, Inc. Macrocyclic ras inhibitors
KR20250029137A (en) 2022-06-22 2025-03-04 주노 쎄러퓨티크스 인코퍼레이티드 Treatment methods for second-line therapy with CD19-targeted CAR T cells
WO2024031091A2 (en) 2022-08-05 2024-02-08 Juno Therapeutics, Inc. Chimeric antigen receptors specific for gprc5d and bcma
IL320217A (en) 2022-10-14 2025-06-01 Black Diamond Therapeutics Inc Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
AR131320A1 (en) 2022-12-13 2025-03-05 Juno Therapeutics Inc Chimeric antigen receptors specific for BAFF-R and CD19 and their methods and uses
TW202504611A (en) 2023-03-30 2025-02-01 美商銳新醫藥公司 Compositions for inducing ras gtp hydrolysis and uses thereof
AU2024243852A1 (en) 2023-04-07 2025-11-06 Revolution Medicines, Inc. Macrocyclic ras inhibitors
AR132338A1 (en) 2023-04-07 2025-06-18 Revolution Medicines Inc RAS INHIBITORS
CN121100123A (en) 2023-04-14 2025-12-09 锐新医药公司 Crystalline form of Ras inhibitors
TW202448897A (en) 2023-04-14 2024-12-16 美商銳新醫藥公司 Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025137507A1 (en) 2023-12-22 2025-06-26 Regor Pharmaceuticals, Inc. Sos1 inhibitors and uses thereof
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000032778A2 (en) * 1998-12-01 2000-06-08 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
WO2001003720A2 (en) * 1999-07-12 2001-01-18 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
US20020146389A1 (en) * 1997-11-18 2002-10-10 Genentech, Inc. DNA19355 polypeptide, a tumor necrosis factor homolog
WO2004073657A2 (en) * 2003-02-19 2004-09-02 Protein Design Labs, Inc. Methods of diagnosis of cancer and other diseases, composition and methods of screening for modulators of cancer and other diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858204B2 (en) * 1999-06-30 2005-02-22 Corxia Corporation Compositions and methods for the therapy and diagnosis of lung cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020146389A1 (en) * 1997-11-18 2002-10-10 Genentech, Inc. DNA19355 polypeptide, a tumor necrosis factor homolog
WO2000032778A2 (en) * 1998-12-01 2000-06-08 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
WO2001003720A2 (en) * 1999-07-12 2001-01-18 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
WO2004073657A2 (en) * 2003-02-19 2004-09-02 Protein Design Labs, Inc. Methods of diagnosis of cancer and other diseases, composition and methods of screening for modulators of cancer and other diseases

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ODOUX C ET AL: "Trail, FASL and a blocking anti-DR5antibody augment paclitxed-induced apoptosis in humna non-small-cell lung cancer", INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 97, no. 4, February 2002 (2002-02-01), pages 458 - 462, XP002989699, ISSN: 0020-7136 *
SPIERINGS DIANA C J ET AL: "Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 15 AUG 2003, vol. 9, no. 9, 15 August 2003 (2003-08-15), pages 3397 - 3405, XP002469336, ISSN: 1078-0432 *
SUN SHI-YONG ET AL: "Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-(3-(1-adamantyl)-4-hydroxyphenyl)-2-naphthalene carboxylic acid (CD437) through up-regulation of TRAIL receptors in human lung cancer cells", CANCER RESEARCH, vol. 60, no. 24, 15 December 2000 (2000-12-15), pages 7149 - 7155, XP002469335, ISSN: 0008-5472 *

Also Published As

Publication number Publication date
JP2007518399A (en) 2007-07-12
WO2005055808A3 (en) 2006-01-26
EP1692318A2 (en) 2006-08-23
WO2005055808A2 (en) 2005-06-23

Similar Documents

Publication Publication Date Title
EP1692318A4 (en) Compositions and methods to diagnose and treat lung cancer
SI1583542T1 (en) Compositions and methods for combination antiviral therapy
EP2671581B8 (en) Compositions and methods for treating cancer
EP1667730A4 (en) Compositions and methods for treating inflammatory lung disease
SG133592A1 (en) Methods for treating prostate cancer with herbal compositions
EP1737482A4 (en) Compositions and methods for treating diseases
GB0411940D0 (en) Methods and compositions
IL169602A0 (en) Methods of treating lung diseases
IL191072A0 (en) Therapeutic compositions and methods
PL2481756T3 (en) Compositions and methods for diagnosing and treating cancer
EP1703907A4 (en) Compositions and methods to treat recurrent medical conditions
EP1468118A4 (en) Methods and compositions for treating cancer
IL176919A0 (en) Methods and compositions for treating cancer
ZA200508655B (en) Compositions and methods relating to stop-1
GB0303609D0 (en) Novel therapeutic method and compositions
GB0308734D0 (en) Uptake of macromolecules
EP1670408A4 (en) Improved obturators
AU2003237792A8 (en) Compositions and methods for the diagnosis and treatment of tumor
GB0324523D0 (en) Compositions and methods of treatment
AU2003298708A8 (en) Gpc99 and gpc99a: methods and compositions for treating cancer
GB2398740B (en) Skin composition
GB0327050D0 (en) Therapeutic methods compositions and uses
ZA200604365B (en) Compositions and methods for the diagnosis and treatment of tumor
GB0329416D0 (en) Treatment of cancer
EP1797430A4 (en) Methods and compositions for the diagnosis and treatment of cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060601

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR LV MK YU

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20080229

17Q First examination report despatched

Effective date: 20081023

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090310